All market news
Medscapeยท48 event signal

FDA Approves Giredestrant + Everolimus for BC in Second-Line

businessBC

The FDA has approved giredestrant (Wilserdly, Roche) with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The combination is...

Put this headline into context

Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.

Source: FreeNewsAPIRead at Medscape

Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.